SOLO:: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

被引:160
作者
Gathe, JC
Ive, P
Wood, R
Schürmann, D
Bellos, NC
DeJesus, E
Gladysz, A
Garris, C
Yeo, J
机构
[1] Therapeut Concepts PA, Houston, TX USA
[2] Clin HIV Res Unit, Parktown, South Africa
[3] Univ Cape Town, Dept Med, ZA-7700 Rondebosch, South Africa
[4] Charite, Campus Virchow Klinikum, Dept Infect Dis, Berlin, Germany
[5] SW Infect Dis Associates, Dallas, TX USA
[6] IDC Res Initiat, Altamonte Springs, FL USA
[7] Univ Wroclaw, Sch Med, Dept Infect Dis, Clin Infect Dis, PL-50138 Wroclaw, Poland
[8] GlaxoSmithKline, Clin Dev & Med Affairs, HIV, Res Triangle Pk, NC USA
关键词
fosamprenavir; ritonavir; nelfinavir; SOLO; protease inhibitor; HIV-1;
D O I
10.1097/01.aids.0000131332.30548.92
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To compare the magnitude and durability of the antiviral response to fosamprenavir (FPV) plus ritonavir (RTV) once-daily (FPV/r QD) with nelfinavir twice-daily (NFV BID), each administered with abacavir and lamivudine twice-daily. Methods: An international, phase III, randomized, open-label study in antiretroviral therapy-naive, HIV-infected adults. Results: Patients with advanced HIV disease received FPV/r QD (n = 322) or NFV BID (n = 327). At week 48, 69% of patients in the FPV/r QD group and 68% in the NFV BID group had plasma HIV-1 RNA (vRNA) < 400 copies/ml, whereas 55% of patients in the FPV/r QD group and 53% in the NFV BID group had vRNA < 50 copies/ml (intent to treat, rebound/discontinuation = failure). More patients in the NFV BID group (17%) experienced virological failure than in the FPV/r QD group (7%). Efficacy of FPV/rQD was maintained in patients with CD4+ cell counts < 50 X 10(6) cells/I or vRNA >= 100000 copies/ml at entry. At week 48, median CD4+ cell counts were increased to 203 X 10(6) cells/I (FPV/r QD group) and 207 X 106 cells/l (NFV BID group). Both regimens were generally well tolerated. Diarrhea was more common on NFV BID than on FPV/r QD (16 versus 9%; P = 0.008). Fasting lipid profile results were generally favorable in both treatment arms. FPV/rQD maintained plasma amprenavir (APV) trough concentrations above the mean phenotypic drug-susceptibility (IC50) for wild-type virus for APV. Conclusion: As a first choice protease inhibitor with a low daily pill burden, FPV/r QD was well tolerated and provided potent, durable antiviral suppression. (C) 2004 Lippincott Williams & Wilkins. Conclusion: As a first choice protease inhibitor with a low daily pill burden, FPV/r QD was well tolerated and provided potent, durable antiviral suppression. (C) 2004 Lippincott Williams & Wilkins.
引用
收藏
页码:1529 / 1537
页数:9
相关论文
共 32 条
[1]  
*AG PHARM, 2003, VIR NELF MES PROD IN
[2]  
Bekker LG, 2003, SAMJ S AFR MED J, V93, P458
[3]  
*CDC, 2000, HIV AIDS SURV REP
[4]   Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy [J].
Chaisson, RE ;
Keruly, JC ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (24) :3128-3129
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]  
DEJESUS E, 2003, 10 C RETR OPP INF BO
[7]   Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study [J].
Durant, J ;
Clevenbergh, P ;
Garraffo, R ;
Halfon, P ;
Icard, S ;
Del Giudice, P ;
Montagne, N ;
Schapiro, JM ;
Dellamonica, P .
AIDS, 2000, 14 (10) :1333-1339
[8]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[9]   Patient adherence to HIV medication regimens: a review of published and abstract reports [J].
Fogarty, L ;
Roter, D ;
Larson, S ;
Burke, J ;
Gillespie, J ;
Levy, R .
PATIENT EDUCATION AND COUNSELING, 2002, 46 (02) :93-108
[10]  
HEMANDEZ J, 2003, 5 INT WORKSH ADV DRU